Risk Factors for the Exacerbation of Esophageal Varices in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma
Patients with EV treatment history, drug-resistant ascites effusion, and EIV and LGV diameters >3.3 and 4.9 mm via CT, respectively, may require careful monitoring for possible EV exacerbation, enabling better EV management, adequate AB therapy, and finally, prolonged patient survival.
Authors
- Hitomi Takada (ORCID: https://orcid.org/0000-0003-2101-0454)
- Shinya Maekawa (ORCID: https://orcid.org/0000-0002-5643-9472)
- Shinichi Takano (ORCID: https://orcid.org/0000-0002-3364-828X)
- Takashi Yoshida (ORCID: https://orcid.org/0000-0003-1119-312X)
- Shōji Kobayashi (ORCID: https://orcid.org/0000-0002-8496-3685)
- Atsunori Tsuchiya (ORCID: https://orcid.org/0000-0002-9279-5917)
- Leona Osawa (ORCID: https://orcid.org/0000-0002-4159-6467)
- Yasuyuki Komiyama
- Masaru Muraoka (ORCID: https://orcid.org/0000-0002-6559-9785)
- Yuichiro Suzuki (ORCID: https://orcid.org/0000-0002-3070-7387)
- Nobuyuki Enomoto
- Mitsuaki Sato
Institutions
- University of Yamanashi (JP)
Publication Details
- Journal
- Oncology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1159/000548667
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00